St. Boniface Hospital clinical trial leads to new commercial product
A clinical trial conducted by Canadian Centre for Agri-Food Research in Health and Medicine (CCARM) Principal Investigator and Medical Microbiologist Dr. Michelle Alfa has contributed to the development of a commercial product, MSPrebiotic®, used for improving gut health in both mid-age and elderly adults. MSPrebiotic® is manufactured in Carberry, Manitoba by MSPrebiotics Inc.
Prebiotics are non-digestible food ingredients that beneficially affect our digestive system by acting as food for probiotics. MSPrebiotic® is an all-natural resistant starch prebiotic that helps improve digestive health by maintaining a good balance of bacteria in the digestive system. Better gut health means better health overall, helping us fight diseases and increase our energy levels and immunities.
Dr. Alfa undertook a Health Canada-cleared prospective, randomized prebiotics clinical trial in partnership with Winnipeg Regional Health Authority’s Medical Director, Rehab & Geriatrics, Dr. David Strang. The trial evaluated the prebiotics in mid-age adults (30 to 50 years of age) as well as elderly (70 years and older) adults. The objective of the clinical trial was to determine if the consumption of MSPrebiotic® could alter microbiomes or decrease glucose and insulin resistance (thereby reducing the risk of Type 2 Diabetes).
The study found that MSPrebiotic® did help improve gut health in participants, and that there was also a significant reduction in blood glucose levels and insulin resistance in older adults. These findings indicate that MSPrebiotic® could be a valuable way to reduce the risk of Type 2 Diabetes.
Congratulations on a successful clinical trial, Dr. Alfa!